| Literature DB >> 22228201 |
Catherine P Haar1, Preetha Hebbar, Gerald C Wallace, Arabinda Das, William A Vandergrift, Joshua A Smith, Pierre Giglio, Sunil J Patel, Swapan K Ray, Naren L Banik.
Abstract
Glioblastoma multiforme (GBM) is recognized as the most common and lethal form of central nervous system cancer. Currently used surgical techniques, chemotherapeutic agents, and radiotherapy strategies have done very little in extending the life expectancies of patients diagnosed with GBM. The difficulty in treating this malignant disease lies both in its inherent complexity and numerous mechanisms of drug resistance. In this review, we summarize several of the primary mechanisms of drug resistance. We reviewed available published literature in the English language regarding drug resistance in glioblastoma. The reasons for drug resistance in glioblastoma include drug efflux, hypoxic areas of tumor cells, cancer stem cells, DNA damage repair, and miRNAs. Many potential therapies target these mechanisms, including a series of investigated alternative and plant-derived agents. Future research and clinical trials in glioblastoma patients should pursue combination of therapies to help combat drug resistance. The emerging new data on the potential of plant-derived therapeutics should also be closely considered and further investigated.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22228201 PMCID： PMC4518733 DOI： 10.1007/s11064-011-0701-1
Source DB: PubMed Journal: Neurochem Res ISSN： 0364-3190 Impact factor: 3.996